MDXH
NASDAQ
$0.42
MDxHealth SA (MDXH)
MDxHealth SA is a prominent biotechnology company focused on precision diagnostics that enhance cancer management, particularly in prostate and bladder cancers. Its leading product, ConfirmMDx for Prostate Cancer, exemplifies the company's commitment to clinical efficacy and personalized medicine, establishing a strong foothold in a rapidly growing market. As the demand for targeted cancer therapies increases, MDxHealth is poised to expand its diagnostic offerings, effectively addressing critical unmet needs in oncology and improving patient outcomes. With its innovative solutions and strategic growth initiatives, MDxHealth is well-positioned to play a vital role in the future of cancer diagnostics.
Sector:
Healthcare
Industry:
Diagnostics & Research
Buy
Target: $2.80 (+571.95%)
Market Cap
$22M
Revenue 5Y CAGR
+42.49%
Free Cash Flow Yield
0.39%
Beta (5Y)
0.84
Price Chart
Valuation
Market Cap$22M
Forward P/E27.70
P/S0.20
P/B23.64
Profitability
Total Revenue (TTM)$163M
Gross Profit (TTM)$71M
EBITDA-$12M
Profit Margin-34.3%
Operating Margin-21.2%
EPS-$1.06
Financial Health
Debt-to-Equity-786.4%
Free Cash Flow Yield0.39%
Growth & Risk
EPS 5Y CAGR-26.30%
Revenue 5Y CAGR+42.49%
Beta (5Y)0.84
Sharpe Ratio-1.54